CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN) at the moment introduced it’ll host a webcast and convention name on Thursday, August 6, 2020 at 5:00 p.m. EDT to debate its second quarter 2020 working and monetary outcomes.
The webcast can be accessible beneath “Occasions & Displays” within the Buyers & Media web page of the Firm’s web site at acceleronpharma.com. People can take part within the convention name by dialing 877-312-5848 (home) or 253-237-1155 (worldwide) and referring to the “Acceleron Second Quarter 2020 Earnings Name.”
The archived webcast can be accessible for replay on the Acceleron web site roughly two hours after the occasion.
Acceleron is a biopharmaceutical firm devoted to the invention, improvement, and commercialization of therapeutics to deal with severe and uncommon ailments. Acceleron’s management within the understanding of TGF-beta superfamily biology and protein engineering generates revolutionary compounds that have interaction the physique’s capacity to manage mobile progress and restore.
Acceleron focuses its commercialization, analysis, and improvement efforts in hematologic and pulmonary ailments. In hematology, REBLOZYL® (luspatercept-aamt) is the primary and solely erythroid maturation agent authorized in the USA and Europe for the therapy of anemia in sure blood problems. REBLOZYL is a part of a world collaboration partnership with Bristol Myers Squibb. The Corporations co-promote REBLOZYL in the USA and are additionally growing luspatercept for the therapy of anemia in affected person populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is growing sotatercept for the therapy of pulmonary arterial hypertension, having just lately reported optimistic topline outcomes of the Part 2 PULSAR trial.